|
|
 |
|
Viewing report
|
|
|
|
Global Markets for Alzheimer's Disease Medications 2005
Millennium Research Group, April 2005
Alzheimer’s Disease (AD) is a neurodegenerative disorder of the central nervous system characterized by the progressive and irreversible loss of nerve cells in brain areas responsible for controlling thought, memory, and language. AD drug medications work to delay the onset of symptoms and slightly improve cognition.
MARKET HIGHLIGHTS
In 2004, the global market for AD medications (consisting of US, France, Germany, Italy, Spain, the UK, and Japan) generated revenues of over $2.6 billion. The US market was the single-largest market for AD drug medications accounting for over half of all global revenues. The global AD drug market will continue to experience strong growth over the forecast period driven by increasing AD prevalence, physician and patient awareness, improved diagnostic tools, increasing prices, the introduction of new AD products, and expanded indications for existing products.
REPORT HIGHLIGHTS
Comprehensive analysis of the market shows impressive growth through to
2009. Examine market trends and issues and detailed segmentation. Assess competitive strengths and weaknesses and anticipate competitor movements.
This report includes:
- sales estimates for expanded indications of Donepezil and Memantine
- a section on new drugs that are currently under development for AD
- leading competitor discussions on market shares for the US, European and
Japanese mild to moderate and moderate to severe markets
- sales estimates segmented by disease severity, region and brand
- prevalence and treated patient estimates from 2003 to 2009 for all regions
- market value forecasts presented in both USD and local currencies (Euros,
Pounds and Yen)
Customers who bought this item also bought
US market size for psoriasis medications by prevalence of moderate-to-severe disease in 2001 forecast to 2006, with forecast patient numbers, dollar sales and operating profits for Genentech Inc's new Xanelim psoriasis drug in 2004 to 2006
Angiogenesis Modulators
Mild Cognitive Impairment - Unlocking the Potential of Prodromal Alzheimer's Disease and Beyond
Global, US and foreign market size for obstructive sleep apnea products, expressed as number of patients with moderate-to-mild OSA and severe OSA for 1997 to 1999 and forecast for 2000 to 2003
Alzheimers Disease - Beta Treatments On The Horizon
Mobile Media Ad Opportunities
Target Product Profiles 2008: Physician Insights on Key Attributes - Alzheimer's Disease (Moderate to Severe)
Mild Cognitive Impairment and Early Alzheimer's Disease: Detection and Diagnosis
Alzheimer Disease - New Drugs, Markets and Companies
Forecast Insight: Insomnia Orexin and Serotonin Receptor Modulators to Innovate Market
Neuroprotection - Drugs, Markets and Companies
Ad-supported Content Services (Part 2): Sizing the Market - Movies
|
|
|
|
